Preventing Heart Disease: The Role of Genetics and Lifestyle

3D polygonal glowing heart alongside a double helix DNA strand symbolizing CRISPR gene editing for heart disease prevention.

Medical Disclaimer: Educational content only. Not medical advice. Consult your doctor for personal health decisions.

Heart Disease Prevention: 

Heart disease prevention is becoming more personalized. Alongside healthy habits, doctors can use additional blood tests and newer treatment evidence to identify risk and guide care. These advances may be especially useful for people with inherited risk or persistently high cholesterol.[acc]

Recent research has also examined whether intensive cholesterol treatment can prevent a first heart attack or stroke in selected high-risk patients. The findings are encouraging, but they do not mean that everyone needs an injectable medicine or advanced testing.[acc]

This article explains what has changed, what the evidence shows, and which questions to discuss with your healthcare professional.

What Is Changing in Heart Disease Prevention?

Traditional prevention focuses on smoking, cholesterol, blood pressure, diabetes, physical activity, and other established risk factors.

These remain important. However, newer guidance also places greater emphasis on inherited cholesterol-related risk, earlier assessment, and choosing treatment according to a person’s overall cardiovascular risk.[acc][learn.acc]

Three developments deserve attention:

  • Evidence that an injectable cholesterol medicine can reduce first cardiovascular events in selected high-risk patients.
  • Broader recommendations for testing lipoprotein(a), an inherited risk marker.
  • More selective use of additional tests to clarify risk and support treatment decisions.[acc][acc]

These are advances in prevention—not proof that heart disease can always be avoided.

1. New Evidence for an Injectable Cholesterol Treatment

Evolocumab is an injectable medicine called a PCSK9 inhibitor. It helps lower LDL cholesterol, often referred to as “bad” cholesterol.[acc][acc]

The VESALIUS-CV trial investigated its benefits in people who had not previously experienced a heart attack or stroke but were already at high cardiovascular risk.[acc]

What did the trial study?

Researchers randomly assigned 12,257 participants to receive evolocumab or a placebo.

Participants had atherosclerosis—disease involving plaque buildup in arteries—or diabetes, and an LDL cholesterol level of at least 90 mg/dL. The median age was 66 years, and follow-up lasted a median of 4.5 years.[acc]

This distinction matters: participants were not a general group of healthy, low-risk adults. Some already had artery disease despite having no previous heart attack or stroke.

What were the results?

Compared with placebo, evolocumab reduced the relative risk of the combined outcome of:

  • Death from coronary heart disease.
  • Heart attack.
  • Ischemic stroke, which occurs when blood flow to part of the brain is blocked.[acc]

The relative reduction for this combined outcome was 25%. This does not mean that every participant’s personal risk fell by 25 percentage points, or that each outcome individually decreased by the same amount.[acc]

What does this mean for patients?

The findings support intensive LDL lowering for selected high-risk patients before a first heart attack or stroke. They do not show that everyone should take evolocumab or replace their existing treatment with it.[acc][acc]

The trial also had limitations. Most participants were White, which limits certainty about how closely the results apply across different populations.[acc]

Treatment decisions still require an individual assessment, including current cholesterol levels, existing medication, health history, and likely benefits.

2. Greater Attention to Inherited Lipoprotein(a)

Lipoprotein(a), usually written as Lp(a), is a cholesterol-carrying particle in the blood. Its level is largely determined by genetics and usually remains relatively stable throughout life.[acc]

A person can have elevated Lp(a) even when their usual LDL cholesterol result does not appear especially high. Measuring it can reveal additional cardiovascular risk that a standard cholesterol assessment may not fully capture.[acc][acc]

What has changed in clinical guidance?

The 2026 American College of Cardiology and American Heart Association dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood. Dyslipidemia means abnormal levels of cholesterol or related blood fats and particles.[acc]

This recommendation aims to help identify inherited risk earlier and support more informed prevention decisions.

Can lifestyle changes lower Lp(a)?

Lifestyle changes generally have little effect on Lp(a) itself. An elevated result is therefore not evidence that someone has eaten poorly or failed to exercise.[acc]

However, healthy habits and management of other risk factors still matter. Your clinician may focus on lowering LDL cholesterol and addressing blood pressure, diabetes, smoking, and other contributors to overall risk.[learn.acc][acc]

An elevated Lp(a) result does not predict exactly whether or when a heart attack will occur. It is one part of a broader assessment.

3. More Personalized Risk Assessment

A cholesterol result is useful, but it does not tell the whole story.

Updated guidance supports combining cholesterol measurements with medical history, family history, and other risk information. In selected cases, additional tests may help clarify whether treatment should be started or intensified.[acc][learn.acc]

Apolipoprotein B testing

Apolipoprotein B, or apoB, can provide additional information about cholesterol-carrying particles associated with artery disease.

The updated guideline supports selective apoB testing, including in some people with diabetes, high triglycerides, or known cardiovascular disease when standard cholesterol results may not fully explain remaining risk.[acc]

This is not a test that every person necessarily needs.

Coronary artery calcium scoring

A coronary artery calcium scan looks for calcium in plaque within the heart’s arteries. Updated guidance supports selective use of this scan to help refine risk assessment and treatment decisions.[acc]

It is not a universal screening requirement or a substitute for urgent assessment of possible heart attack symptoms.

How Genetics and Lifestyle Fit Together

New clinical tools do not make healthy habits less important.

Earlier research involving more than 55,000 participants found that a favorable lifestyle was associated with lower coronary risk across genetic risk groups. Among those with high genetic risk, a favorable lifestyle was associated with a 46% lower relative risk of coronary events than an unfavorable lifestyle.[pubmed.ncbi.nlm.nih]

The study assessed four factors:

  • Not currently smoking.
  • Not having obesity.
  • Regular physical activity.
  • A healthy diet.[pubmed.ncbi.nlm.nih]

Because this was observational research, it cannot prove that lifestyle alone caused the difference. It also does not mean that healthy habits remove all inherited risk.

The useful message is that genetics and lifestyle should not be treated as competing explanations. Both can influence prevention decisions.

What These Advances Do Not Mean

Clinical research can be promising without providing a solution for everyone.

Keep these distinctions in mind:

  • A successful trial in high-risk patients does not establish the same benefit in low-risk adults.[acc]
  • A relative risk reduction is not the same as an absolute percentage-point reduction.[acc]
  • Elevated Lp(a) indicates increased risk, not a guaranteed future heart attack.[acc][acc]
  • Additional testing should inform a clinical decision rather than be ordered automatically.[acc]
  • Medicines, monitoring, and healthy habits can work together; they are not interchangeable.[learn.acc]

Avoid changing treatment based only on a headline or a single research result.

Questions to Ask Your Healthcare Professional

A consultation can help turn research into a practical plan.

Consider asking:

  1. What is my overall cardiovascular risk?
  2. Does my family history suggest inherited cholesterol risk?
  3. Have I had an Lp(a) measurement?
  4. Are my LDL cholesterol and blood pressure adequately managed?
  5. Would apoB testing or a calcium scan change my treatment?
  6. Is my current medication sufficient?
  7. What benefits, side effects, and costs should I understand before changing treatment?

Not everyone will need every test or treatment discussed in this article.

When to Seek Medical Advice

Arrange a routine appointment if you have a family history of early heart disease, a relative with familial hypercholesterolemia, or concerns about cholesterol, blood pressure, or diabetes. These factors can help your clinician decide whether earlier or more detailed assessment is appropriate.[learn.acc][cdc][cdc]

Possible heart attack symptoms need emergency care

Call your local emergency number immediately for possible warning signs such as:

  • Chest pressure, squeezing, fullness, or pain.
  • Discomfort spreading to the arms, back, neck, jaw, or stomach.
  • Shortness of breath.
  • Cold sweat, nausea, or lightheadedness.[heart]

Symptoms vary between individuals. Chest discomfort remains the most common heart attack symptom in both women and men, but other symptoms can occur. Do not wait for a routine appointment if you suspect a heart attack.[heart][heart]

Key Takeaways and Doctor Consultation Advice

  • Treatment evidence is expanding: Evolocumab reduced a combined measure of first cardiovascular events in selected high-risk patients without a previous heart attack or stroke.[acc]
  • Inherited risk deserves attention: Updated US guidance recommends measuring Lp(a) at least once in adulthood.[acc]
  • Testing should have a purpose: ApoB testing and calcium scans may help selected patients, but they are not necessary for everyone.[acc]
  • Lifestyle still matters: Healthy habits remain a foundation of cardiovascular prevention, including for people with inherited risk.[learn.acc][pubmed.ncbi.nlm.nih]
  • Ask for individual advice: Everyone’s symptoms, family history, test results, and treatment needs differ. A qualified healthcare professional can help decide which developments apply to you.
  • Recognize emergencies: Possible heart attack symptoms require immediate medical attention.[heart]

Frequently Asked Questions

Is evolocumab suitable for everyone?

No. The trial discussed here involved selected high-risk patients with atherosclerosis or diabetes and elevated LDL cholesterol. Its findings should not be applied automatically to healthy, low-risk adults.[acc]

Is an Lp(a) test the same as a genetic test?

No. It measures the amount of lipoprotein(a) in your blood rather than directly analyzing your DNA. The result can still provide useful information about a largely inherited risk factor.[acc]

Can healthy eating remove inherited heart disease risk?

No. Healthy habits can reduce overall risk, but they do not eliminate every inherited factor. Lifestyle changes also have minimal effect on Lp(a) levels themselves.[acc][pubmed.ncbi.nlm.nih]

Should I request every advanced heart test?

Not necessarily. Testing is most useful when the result could change a prevention or treatment decision. Discuss the purpose, limitations, and likely next steps with your clinician.[acc][learn.acc]

Conclusion

Advances in heart disease prevention are helping clinicians identify inherited risk and choose treatment more precisely.

The most useful next step is not to request every new test or medicine. It is to understand your own risk and discuss which evidence-based options could improve your care.[acc][learn.acc]

Editorial Note and Medical Disclaimer

This article provides general health education based on published research and publicly available guidance from the American College of Cardiology, the American Heart Association, and the Centers for Disease Control and Prevention.

A clinical trial result, guideline recommendation, and individual treatment decision are different things. Benefits and risks depend on the person, and treatment availability may vary by country and healthcare system.

This article does not diagnose a condition or recommend a specific medicine for an individual. Consult a qualified healthcare professional before changing treatment. Seek emergency care for possible heart attack symptoms.

The organizations and researchers cited have not endorsed this article. A medical reviewer’s name or credentials should appear only if that person has actually reviewed the content.

References

    1. American College of Cardiology. “VESALIUS-CV: Evolocumab vs. Placebo in Patients Without Previous MI or Stroke.” November 2025. Summary of trial design, results, and limitations.[acc]
    2. Bohula EA, Marston NA, Bhatia AK, et al. “Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.” New England Journal of Medicine. Published online November 8, 2025. doi:10.1056/NEJMoa2514428. Publication details reported by the American College of Cardiology.[acc]
    3. American College of Cardiology. “ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol.” March 2026.[acc]
    4. American College of Cardiology. “Lower Sooner: How the 2026 Dyslipidemia Guideline Changes Practice.” July 2026.[acc]
    5. American College of Cardiology. Overview of the “2026 Guideline on the Management of Dyslipidemia.”[learn.acc]
    6. Khera AV, Emdin CA, Drake I, et al. “Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease.” New England Journal of Medicine. 2016;375:2349–2358. doi:10.1056/NEJMoa1605086.[pubmed.ncbi.nlm.nih]
    7. American Heart Association. “Warning Signs of a Heart Attack.”[heart]
    8. American Heart Association. “Heart Attack Symptoms in Women.”[heart]

Leave A Comment